Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States-Reference-Cited by-同舟云学术

Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States

Published:2021-12-27 Issue: Volume: Page:1-12
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Thornburg Courtney D¹,Adamski Kelly²,Cook Keziah³,Vembusubramanian Mohini²,Sendhil Selvam R²,Hinds David⁴,Chen Er⁴,Sammon Joshua⁴,Solari Paul⁴,Garrison Louis P⁵,Croteau Stacy E⁶

Affiliation:

1. Division of Pediatric Hematology/Oncology, Rady Children’s Hospital-San Diego, San Diego, CA, and Department of Pediatrics, UC San Diego School of Medicine, La Jolla, CA.

2. Analysis Group, Inc., Los Angeles, CA.

3. Analysis Group, Inc., Menlo Park, CA.

4. BioMarin Pharmaceutical Inc., Novato, CA.

5. CHOICE Institute, Department of Pharmacy, University of Washington, Seattle.

6. Division of Hematology-Oncology, Boston Children’s Hospital/Harvard Medical School, Boston, MA.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B;Journal of Managed Care & Specialty Pharmacy;2024-06-26

2. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data;Journal of Medical Economics;2023-10-25

3. Psychometrics and applications of a novel self‐report measure of emicizumab adherence: VERITASNexGen;Haemophilia;2023-08-30

4. Health care costs and resource use of managing hemophilia A: A targeted literature review;Journal of Managed Care & Specialty Pharmacy;2023-06

5. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors;Journal of Medical Economics;2022-08-01